Safety and efficacy of eribulin mesylate in patients with extra cranial metastatic breast cancer

Trial Profile

Safety and efficacy of eribulin mesylate in patients with extra cranial metastatic breast cancer

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jul 2016 New trial record
    • 07 Jun 2016 Preliminary results (n=30) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top